Exploring Chronic Lymphocytic Leukemia (CLL) in elderly patients, its diagnosis, revolutionary treatments, and future research directions.
Phase I trial reveals dual targeting of BTK and CD52 achieves MRD negativity in high-risk CLL but with significant infection risks